I, Jason Napodano, CFA, hereby certify that all views expressed on this or any other blog, or in my Twitter, accurately reflect my personal views about the subject securities. I believe the information used for the creation of articles for this or any other blog or tweets has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed on this or any other blog or via Twitter are subject to change without notice.
At times, I submit articles under Seeking Alpha's Premium or Pro programs, which pays on a per click or set rate per article. I receive compensation from Google Adsense for advertising seen on this blog. At times I own stock in securities that I write about. All reports or articles will always disclose my position if I am long or short the stock. Readers of this blog can assume that no disclosed position means I am neither long nor short the common stock.
REFERRALS AND FEES FOR SERVICE
I hold no FINRA or SEC securities licenses. I do not provide nor have I received compensation for investment banking services on the securities covered on this blog or via my Twitter. I do not expect to receive compensation for investment banking services from issues covered by this blog or via my Twitter.
BioNap Consulting, Inc. may have been paid a fee by some of the companies featured on this blog. These fees include, but are not limited to, introductions to research analysts, brokers, institutional investors and money managers, providing strategic advisory services with respect to investor relations, writing white papers or information articles, and providing due diligence services such as market research and valuation / fairness opinions for licensing or M&A transactions. Since I may have been compensated for these services, investors should evaluate the information on this blog with that in mind and should always perform their own independent analysis.
The purpose of this blog is to provide fair and accurate information on these subject companies. My analysis is designed to explain the diseases, the science behind the drugs, and the market opportunity so that investors can make informed decisions. My articles will often cover clinical data where I am extrapolating to commercial use and implying success or failure, but keep in mind these are my opinions only and investors should perform their own due diligence to back-up for refute my work. For these due diligence and intelligence services, companies hire BioNap Consulting and pay fees in cash and/or stock. Past and/or current clients of BioNap Consulting, Inc. include: Can-Fite Biopharma, Immune Pharmaceuticals, Titan Pharmaceuticals, Actinium Pharmaceuticals, Briacell Therapeutics, RedHill Biopharma, Oryzon Genomics, Synchroneuron, and Nuvo Research Inc.
This blog is for informational purposes only. Articles and Tweets are based on publicly available information obtained from sources I believe to be reliable, but I cannot guarantee to be accurate nor do I purport to be complete. Because of individual objectives, articles or Tweets should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk, and investment in biotechnology stocks involves significant risk. Investors should be aware of these risks and consult a certified financial planner (CFP) before making investment decisions. I am not a CFP.
By visiting this blog or my Twitter, investors understand and assume full responsibility for this disclaimer. Any opinions expressed on this blog or via my Twitter are subject to change without notice. Articles or Tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities mentioned herein. Additional information is available upon request.
RATING & RECOMMENDATION
I may use the following rating system for securities covered on the blog:
- Buy: I expect the stock to go higher.
- Hold: I expect the stock to trend side ways.
- Neutral: I believe the risk / reward is balanced.
- Sell: I think the stock is going lower.
Often, reports or articles will have target prices. I do my best to fully explain how these targets are derived. Ratings or price targets reported on Twitter are associated with articles found or linked within this blog, or articles published on websites such as Seeking-Alpha. A rough estimate of the distribution for securities covered on this blog is: Buy- 50%, Hold/Neutral- 25%, Sell- 5%, No rating - 20%.
Articles where BioNap Consulting, Inc. has provided intelligence, due diligence, or advisory services will not contain a rating or price target, but may contain valuation models and market research suggesting things like peak sales opportunity or projected market share. BioNap expressly cautions investors from taking investment advice on subject companies where BioNap has been paid an advisory fee.
To learn more about me, visit the About Me tab above.
Jason Napodano, CFA